-
1
-
-
84891785971
-
Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial
-
Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.32
, pp. 4085-4091
-
-
Gilbert, M.R.1
Wang, M.2
Aldape, K.D.3
-
2
-
-
84862934329
-
Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets
-
Mao H, Lebrun DG, Yang J, et al. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48-56.
-
(2012)
Cancer Invest.
, vol.30
, Issue.1
, pp. 48-56
-
-
Mao, H.1
Lebrun, D.G.2
Yang, J.3
-
3
-
-
84894194756
-
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
-
Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
-
(2014)
N Engl J Med.
, vol.370
, Issue.8
, pp. 709-722
-
-
Chinot, O.L.1
Wick, W.2
Mason, W.3
-
4
-
-
84894114159
-
A randomized trial of bevacizumab for newly diagnosed glioblastoma
-
Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
-
(2014)
N Engl J Med.
, vol.370
, Issue.8
, pp. 699-708
-
-
Gilbert, M.R.1
Dignam, J.J.2
Armstrong, T.S.3
-
5
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
-
(2010)
N Engl J Med.
, vol.363
, Issue.5
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
-
6
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
-
(2010)
N Engl J Med.
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
7
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
-
(2012)
N Engl J Med.
, vol.366
, Issue.26
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
8
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
-
(2012)
N Engl J Med.
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
9
-
-
84876325876
-
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
-
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
-
(2013)
N Engl J Med.
, vol.368
, Issue.16
, pp. 1509-1518
-
-
Grupp, S.A.1
Kalos, M.2
Barrett, D.3
-
10
-
-
84863337890
-
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
-
Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
-
(2012)
Blood
, vol.119
, Issue.12
, pp. 2709-2720
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Feldman, S.A.3
-
11
-
-
0034754259
-
Fever and cancer in perspective
-
Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother. 2001;50:391-396.
-
(2001)
Cancer Immunol Immunother
, vol.50
, pp. 391-396
-
-
Hobohm, U.1
-
12
-
-
0000161413
-
The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases
-
Coley WB. The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases. Am J Med Sci. 1893;105:487-511.
-
(1893)
Am J Med Sci.
, vol.105
, pp. 487-511
-
-
Coley, W.B.1
-
13
-
-
0014066035
-
Spontaneous regression of malignant disease: Report of three cases
-
Margolis J, West D. Spontaneous regression of malignant disease: report of three cases. J Am Geriatr Soc. 1967;15(3):251-253.
-
(1967)
J Am Geriatr Soc.
, vol.15
, Issue.3
, pp. 251-253
-
-
Margolis, J.1
West, D.2
-
14
-
-
80053641609
-
Postoperative infection may influence survival in patients with glioblastoma: Simply a myth?
-
discussion 868-869
-
De Bonis P, Albanese A, Lofrese G, et al. Postoperative infection may influence survival in patients with glioblastoma: simply a myth?. Neurosurg. 2011;69(4):864-868. discussion 868-869.
-
(2011)
Neurosurg
, vol.69
, Issue.4
, pp. 864-868
-
-
De Bonis, P.1
Albanese, A.2
Lofrese, G.3
-
15
-
-
67650071214
-
IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era
-
Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009;125(3):680-687.
-
(2009)
Int J Cancer
, vol.125
, Issue.3
, pp. 680-687
-
-
Wiemels, J.L.1
Wilson, D.2
Patil, C.3
-
16
-
-
35548956467
-
Atopy and risk of brain tumors: A meta-analysis
-
Linos E, Raine T, Alonso A, et al. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544-1550.
-
(2007)
J Natl Cancer Inst.
, vol.99
, Issue.20
, pp. 1544-1550
-
-
Linos, E.1
Raine, T.2
Alonso, A.3
-
17
-
-
33646242019
-
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival
-
Wrensch M, Wiencke JK, Wiemels J, et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 2006;66(8):4531-4541.
-
(2006)
Cancer Res.
, vol.66
, Issue.8
, pp. 4531-4541
-
-
Wrensch, M.1
Wiencke, J.K.2
Wiemels, J.3
-
18
-
-
84859883741
-
Cancer and innate immune system interactions: Translational potentials for cancer immunotherapy
-
Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother. 2012;35(4):299-308.
-
(2012)
J Immunother
, vol.35
, Issue.4
, pp. 299-308
-
-
Liu, Y.1
Zeng, G.2
-
19
-
-
78651010946
-
Immunity to hemologous grafted skin: III. The fate of skin hemografts transplanted to the brain, to subcutaneous tissue, and toe the anterior chamber of the eye
-
Medawar P. Immunity to hemologous grafted skin: III. The fate of skin hemografts transplanted to the brain, to subcutaneous tissue, and toe the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
-
(1948)
Br J Exp Pathol.
, vol.29
, pp. 58-69
-
-
Medawar, P.1
-
20
-
-
77951837763
-
Trafficking of immune cells in the central nervous system
-
Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120(5):1368-1379.
-
(2010)
J Clin Invest.
, vol.120
, Issue.5
, pp. 1368-1379
-
-
Wilson, E.H.1
Weninger, W.2
Hunter, C.A.3
-
22
-
-
0025981021
-
T-lymphocyte entry into the central nervous system
-
Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res. 1991;28(2):254-260.
-
(1991)
J Neurosci Res.
, vol.28
, Issue.2
, pp. 254-260
-
-
Hickey, W.F.1
Hsu, B.L.2
Kimura, H.3
-
23
-
-
33748743268
-
CNS immune privilege: Hiding in plain sight
-
Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48-65.
-
(2006)
Immunol Rev.
, vol.213
, pp. 48-65
-
-
Carson, M.J.1
Doose, J.M.2
Melchior, B.3
-
24
-
-
0036316548
-
Blood-brain barrier breakdown in septic encephalopathy and brain tumours
-
Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 2002;200(6):639-646.
-
(2002)
J Anat.
, vol.200
, Issue.6
, pp. 639-646
-
-
Davies, D.C.1
-
25
-
-
0036942718
-
Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: Spatial segregation of tenascin and agrin
-
Rascher G, Fischmann A, Kroger S, et al. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 2002;104(1):85-91.
-
(2002)
Acta Neuropathol.
, vol.104
, Issue.1
, pp. 85-91
-
-
Rascher, G.1
Fischmann, A.2
Kroger, S.3
-
26
-
-
60549104213
-
Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE
-
van Zwam M, Huizinga R, Melief MJ, et al. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl). 2009;87(3):273-286.
-
(2009)
J Mol Med (Berl)
, vol.87
, Issue.3
, pp. 273-286
-
-
Van Zwam, M.1
Huizinga, R.2
Melief, M.J.3
-
27
-
-
33751503037
-
T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa
-
Goldmann J, Kwidzinski E, Brandt C, et al. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leuk Biol. 2006;80(4):797-801.
-
(2006)
J Leuk Biol.
, vol.80
, Issue.4
, pp. 797-801
-
-
Goldmann, J.1
Kwidzinski, E.2
Brandt, C.3
-
28
-
-
0026929035
-
Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance
-
Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992;2(4):269-276.
-
(1992)
Brain Pathol.
, vol.2
, Issue.4
, pp. 269-276
-
-
Cserr, H.F.1
Harling-Berg, C.J.2
Knopf, P.M.3
-
29
-
-
45849130520
-
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
-
Prins RM, Shu CJ, Radu CG, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008;57(9):1279-1289.
-
(2008)
Cancer Immunol Immunother.
, vol.57
, Issue.9
, pp. 1279-1289
-
-
Prins, R.M.1
Shu, C.J.2
Radu, C.G.3
-
30
-
-
84865469861
-
T cells become licensed in the lung to enter the central nervous system
-
Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the central nervous system. Nature. 2012;488(7413):675-679.
-
(2012)
Nature.
, vol.488
, Issue.7413
, pp. 675-679
-
-
Odoardi, F.1
Sie, C.2
Streyl, K.3
-
31
-
-
34548807135
-
Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells
-
Masson F, Calzascia T, Di Berardino-Besson W, et al. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 2007;179(2):845-853.
-
(2007)
J Immunol.
, vol.179
, Issue.2
, pp. 845-853
-
-
Masson, F.1
Calzascia, T.2
Di Berardino-Besson, W.3
-
32
-
-
3242658002
-
Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells
-
Kulprathipanja NV, Kruse CA. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells. J Neuroimmunol. 2004;153(1-2):76-82.
-
(2004)
J Neuroimmunol.
, vol.153
, Issue.1-2
, pp. 76-82
-
-
Kulprathipanja, N.V.1
Kruse, C.A.2
-
33
-
-
0032925357
-
Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation
-
Carson MJ, Sutcliffe JG, Campbell IL. Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J Neurosci Res. 1999;55(1):127-134.
-
(1999)
J Neurosci Res.
, vol.55
, Issue.1
, pp. 127-134
-
-
Carson, M.J.1
Sutcliffe, J.G.2
Campbell, I.L.3
-
34
-
-
61449224570
-
Microglia: Gatekeepers of central nervous system immunology
-
Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol. 2009;85(3):352-370.
-
(2009)
J Leukoc Biol.
, vol.85
, Issue.3
, pp. 352-370
-
-
Tambuyzer, B.R.1
Ponsaerts, P.2
Nouwen, E.J.3
-
35
-
-
4043144986
-
Initiation of immune responses in brain is promoted by local dendritic cells
-
Karman J, Ling C, Sandor M, et al. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol. 2004;173(4):2353-2361.
-
(2004)
J Immunol.
, vol.173
, Issue.4
, pp. 2353-2361
-
-
Karman, J.1
Ling, C.2
Sandor, M.3
-
36
-
-
33748532939
-
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
-
Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006;8(3):261-279.
-
(2006)
Neuro Oncol.
, vol.8
, Issue.3
, pp. 261-279
-
-
Hussain, S.F.1
Yang, D.2
Suki, D.3
-
37
-
-
80053898650
-
Of mice and men: Experimental autoimmune encephalitis and multiple sclerosis
-
Handel AE, Lincoln MR, Ramagopalan SV. Of mice and men: experimental autoimmune encephalitis and multiple sclerosis. Eur J Clin Inv. 2011;41(11):1254-1258.
-
(2011)
Eur J Clin Inv.
, vol.41
, Issue.11
, pp. 1254-1258
-
-
Handel, A.E.1
Lincoln, M.R.2
Ramagopalan, S.V.3
-
38
-
-
84855604775
-
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment
-
Jackson C, Ruzevick J, Phallen J, et al. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Develop Immunol. 2011;2011:732413.
-
(2011)
Clin Develop Immunol.
, vol.2011
, pp. 732413
-
-
Jackson, C.1
Ruzevick, J.2
Phallen, J.3
-
39
-
-
33847052535
-
Mechanisms of malignant glioma immune resistance and sources of immunosuppression
-
Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10(A):133-146.
-
(2006)
Gene Ther Mol Biol.
, vol.10
, Issue.A
, pp. 133-146
-
-
Gomez, G.G.1
Kruse, C.A.2
-
40
-
-
70450213189
-
Glioblastoma-derived mechanisms of systemic immunosuppression
-
Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin NA. 2010;21(1):31-42.
-
(2010)
Neurosurg Clin NA.
, vol.21
, Issue.1
, pp. 31-42
-
-
Waziri, A.1
-
41
-
-
79955640835
-
Mechanisms of immunomodulation in human glioblastoma
-
Avril T, Vauleon E, Tanguy-Royer S, et al. Mechanisms of immunomodulation in human glioblastoma. Immunotherapy. 2011;3(4 Suppl):42-44.
-
(2011)
Immunotherapy
, vol.3
, Issue.4
, pp. 42-44
-
-
Avril, T.1
Vauleon, E.2
Tanguy-Royer, S.3
-
42
-
-
0033398454
-
Immune defects observed in patients with primary malignant brain tumors
-
Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100(1-2):216-232.
-
(1999)
J Neuroimmunol.
, vol.100
, Issue.1-2
, pp. 216-232
-
-
Dix, A.R.1
Brooks, W.H.2
Roszman, T.L.3
-
43
-
-
33645502885
-
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
-
Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294-3302.
-
(2006)
Cancer Res.
, vol.66
, Issue.6
, pp. 3294-3302
-
-
Fecci, P.E.1
Mitchell, D.A.2
Whitesides, J.F.3
-
44
-
-
5444230303
-
T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors
-
Kempuraj D, Devi RS, Madhappan B, et al. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopath Pharmacol. 2004;17(1):57-64.
-
(2004)
Int J Immunopath Pharmacol.
, vol.17
, Issue.1
, pp. 57-64
-
-
Kempuraj, D.1
Devi, R.S.2
Madhappan, B.3
-
45
-
-
80051693219
-
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide
-
Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473-5480.
-
(2011)
Clin Cancer Res.
, vol.17
, Issue.16
, pp. 5473-5480
-
-
Grossman, S.A.1
Ye, X.2
Lesser, G.3
-
46
-
-
25444471021
-
Impaired capacity for upregulation of MHC class II in tumor-associated microglia
-
Schartner JM, Hagar AR, Van Handel M, et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005;51(4):279-285.
-
(2005)
Glia
, vol.51
, Issue.4
, pp. 279-285
-
-
Schartner, J.M.1
Hagar, A.R.2
Van Handel, M.3
-
47
-
-
28544444135
-
Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors
-
Facoetti A, Nano R, Zelini P, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res. 2005;11(23):8304-8311.
-
(2005)
Clin Cancer Res.
, vol.11
, Issue.23
, pp. 8304-8311
-
-
Facoetti, A.1
Nano, R.2
Zelini, P.3
-
48
-
-
0026541255
-
Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia
-
Constam DB, Philipp J, Malipiero UV, et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148(5):1404-1410.
-
(1992)
J Immunol.
, vol.148
, Issue.5
, pp. 1404-1410
-
-
Constam, D.B.1
Philipp, J.2
Malipiero, U.V.3
-
49
-
-
0032741283
-
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
-
Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5(10):2963-2970.
-
(1999)
Clin Cancer Res.
, vol.5
, Issue.10
, pp. 2963-2970
-
-
Gabrilovich, D.I.1
Ishida, T.2
Nadaf, S.3
-
50
-
-
0025196599
-
In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
-
Sawamura Y, Diserens AC, de Tribolet N. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol. 1990;9(2):125-130.
-
(1990)
J Neurooncol.
, vol.9
, Issue.2
, pp. 125-130
-
-
Sawamura, Y.1
Diserens, A.C.2
De Tribolet, N.3
-
51
-
-
0028888764
-
Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas
-
Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol. 1995;146(2):317-322.
-
(1995)
Am J Pathol.
, vol.146
, Issue.2
, pp. 317-322
-
-
Huettner, C.1
Paulus, W.2
Roggendorf, W.3
-
52
-
-
77953798698
-
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development
-
Tran Thang NN, Derouazi M, Philippin G, et al. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res. 2010;70(12):4829-4839.
-
(2010)
Cancer Res.
, vol.70
, Issue.12
, pp. 4829-4839
-
-
Tran Thang, N.N.1
Derouazi, M.2
Philippin, G.3
-
53
-
-
0028807156
-
Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
-
discussion 1166-1167
-
Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurg. 1995;37(6):1160-1166. discussion 1166-1167.
-
(1995)
Neurosurg.
, vol.37
, Issue.6
, pp. 1160-1166
-
-
Hishii, M.1
Nitta, T.2
Ishida, H.3
-
54
-
-
34248529706
-
Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1
-
Roth P, Mittelbronn M, Wick W, et al. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res. 2007;67(8):3540-3544.
-
(2007)
Cancer Res.
, vol.67
, Issue.8
, pp. 3540-3544
-
-
Roth, P.1
Mittelbronn, M.2
Wick, W.3
-
55
-
-
52649169692
-
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
-
Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14(16):5166-5172.
-
(2008)
Clin Cancer Res.
, vol.14
, Issue.16
, pp. 5166-5172
-
-
Heimberger, A.B.1
Abou-Ghazal, M.2
Reina-Ortiz, C.3
-
56
-
-
33748481603
-
An increase in CD4+CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme
-
El Andaloussi A, Lesniak MS. An increase in CD4+CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8(3):234-243.
-
(2006)
Neuro Oncol.
, vol.8
, Issue.3
, pp. 234-243
-
-
El Andaloussi, A.1
Lesniak, M.S.2
-
57
-
-
84860358785
-
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: Implications for immunotherapy
-
Crane CA, Ahn BJ, Han SJ, et al. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol. 2012;14(5):584-595.
-
(2012)
Neuro Oncol.
, vol.14
, Issue.5
, pp. 584-595
-
-
Crane, C.A.1
Ahn, B.J.2
Han, S.J.3
-
58
-
-
77955658133
-
Prognostic significance and mechanism of Treg infiltration in human brain tumors
-
Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol. 2010;225(1-2):195-199.
-
(2010)
J Neuroimmunol.
, vol.225
, Issue.1-2
, pp. 195-199
-
-
Jacobs, J.F.1
Idema, A.J.2
Bol, K.F.3
-
59
-
-
0035879509
-
Role of microglia in glioma biology
-
Badie B, Schartner J. Role of microglia in glioma biology. Microscopy Res Tech. 2001;54(2):106-113.
-
(2001)
Microscopy Res Tech.
, vol.54
, Issue.2
, pp. 106-113
-
-
Badie, B.1
Schartner, J.2
-
60
-
-
84864709456
-
The molecular profile of microglia under the influence of glioma
-
Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol. 2012;14(8):958-978.
-
(2012)
Neuro Oncol.
, vol.14
, Issue.8
, pp. 958-978
-
-
Li, W.1
Graeber, M.B.2
-
61
-
-
79251620102
-
Hypoxia potentiates glioma-mediated immunosuppression
-
Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PloS One. 2011;6(1):e16195.
-
(2011)
PloS One.
, vol.6
, Issue.1
, pp. e16195
-
-
Wei, J.1
Wu, A.2
Kong, L.Y.3
-
62
-
-
33646879823
-
T-cell apoptosis in human glioblastoma multiforme: Implications for immunotherapy
-
Walker DG, Chuah T, Rist MJ, et al. T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J Neuroimmunol. 2006;175(1-2):59-68.
-
(2006)
J Neuroimmunol.
, vol.175
, Issue.1-2
, pp. 59-68
-
-
Walker, D.G.1
Chuah, T.2
Rist, M.J.3
-
63
-
-
77954741566
-
FasL gene knock-down therapy enhances the antiglioma immune response
-
Jansen T, Tyler B, Mankowski JL, et al. FasL gene knock-down therapy enhances the antiglioma immune response. Neuro Oncol. 2010;12(5):482-489.
-
(2010)
Neuro Oncol.
, vol.12
, Issue.5
, pp. 482-489
-
-
Jansen, T.1
Tyler, B.2
Mankowski, J.L.3
-
64
-
-
42649125225
-
PD-1 and its ligands in tolerance and immunity
-
Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. 2008;26:677-704.
-
(2008)
Ann Rev Immunol.
, vol.26
, pp. 677-704
-
-
Keir, M.E.1
Butte, M.J.2
Freeman, G.J.3
-
65
-
-
77953679701
-
Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation
-
Molldrem J, Riddell S. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. Ca Treat Res. 2009;144:187-208.
-
(2009)
Ca Treat Res.
, vol.144
, pp. 187-208
-
-
Molldrem, J.1
Riddell, S.2
-
66
-
-
0025678601
-
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
-
Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
-
(1990)
Blood
, vol.76
, Issue.12
, pp. 2462-2465
-
-
Kolb, H.J.1
Mittermuller, J.2
Clemm, C.3
-
67
-
-
77649221824
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
-
Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
-
(2010)
Blood
, vol.115
, Issue.5
, pp. 925-935
-
-
Heslop, H.E.1
Slobod, K.S.2
Pule, M.A.3
-
68
-
-
0023115642
-
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
-
Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889-897.
-
(1987)
N Engl J Med.
, vol.316
, Issue.15
, pp. 889-897
-
-
Rosenberg, S.A.1
Lotze, M.T.2
Muul, L.M.3
-
69
-
-
20244366111
-
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
-
Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.10
, pp. 2346-2357
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Yang, J.C.3
-
70
-
-
0031832638
-
Systemic T cell adoptive immunotherapy of malignant gliomas
-
Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998;89(1):42-51.
-
(1998)
J Neurosurg
, vol.89
, Issue.1
, pp. 42-51
-
-
Plautz, G.E.1
Barnett, G.H.2
Miller, D.W.3
-
71
-
-
0034044202
-
T cell adoptive immunotherapy of newly diagnosed gliomas
-
Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000;6(6):2209-2218.
-
(2000)
Clin Cancer Res.
, vol.6
, Issue.6
, pp. 2209-2218
-
-
Plautz, G.E.1
Miller, D.W.2
Barnett, G.H.3
-
72
-
-
0041833713
-
Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas
-
Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res. 2003;9(9):3294-3302.
-
(2003)
Clin Cancer Res.
, vol.9
, Issue.9
, pp. 3294-3302
-
-
Tsuboi, K.1
Saijo, K.2
Ishikawa, E.3
-
73
-
-
84856845120
-
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma
-
Ghazi A, Ashoori A, Hanley PJ, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012;35(2):159-168.
-
(2012)
J Immunother.
, vol.35
, Issue.2
, pp. 159-168
-
-
Ghazi, A.1
Ashoori, A.2
Hanley, P.J.3
-
74
-
-
77956535599
-
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
-
Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035-1044.
-
(2010)
Blood
, vol.116
, Issue.7
, pp. 1035-1044
-
-
Jena, B.1
Dotti, G.2
Cooper, L.J.3
-
75
-
-
80054680991
-
Treating cancer with genetically engineered T cells
-
Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2010;29(11):550-557.
-
(2010)
Trends Biotechnol.
, vol.29
, Issue.11
, pp. 550-557
-
-
Park, T.S.1
Rosenberg, S.A.2
Morgan, R.A.3
-
76
-
-
84863085396
-
CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe
-
Gilham DE, Debets R, Pule M, et al. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med. 2012;18(7):377-384.
-
(2012)
Trends Mol Med.
, vol.18
, Issue.7
, pp. 377-384
-
-
Gilham, D.E.1
Debets, R.2
Pule, M.3
-
77
-
-
77950475517
-
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
-
Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
-
(2010)
Mol Ther.
, vol.18
, Issue.4
, pp. 843-851
-
-
Morgan, R.A.1
Yang, J.C.2
Kitano, M.3
-
78
-
-
84868583378
-
Model T muscle CARs can treat brain tumors
-
Johnson LA. Model T muscle CARs can treat brain tumors. Clin Cancer Res. 2012;18(21):5834-5836.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.21
, pp. 5834-5836
-
-
Johnson, L.A.1
-
79
-
-
84859820456
-
Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells
-
Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012;18(8):2199-2209.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.8
, pp. 2199-2209
-
-
Brown, C.E.1
Starr, R.2
Aguilar, B.3
-
80
-
-
84868576774
-
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells
-
Kong S, Sengupta S, Tyler B, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res. 2012;18(21):5949-5960.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.21
, pp. 5949-5960
-
-
Kong, S.1
Sengupta, S.2
Tyler, B.3
-
81
-
-
78650721870
-
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma
-
Jin J, Joo KM, Lee SJ, et al. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep. 2011;25(1):33-39.
-
(2011)
Oncol Rep.
, vol.25
, Issue.1
, pp. 33-39
-
-
Jin, J.1
Joo, K.M.2
Lee, S.J.3
-
82
-
-
84875215925
-
T cells redirected to EphA2 for the immunotherapy of glioblastoma
-
Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21(3):629-637.
-
(2013)
Mol Ther.
, vol.21
, Issue.3
, pp. 629-637
-
-
Chow, K.K.1
Naik, S.2
Kakarla, S.3
-
83
-
-
84875198775
-
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
-
Morgan RA, Johnson LA, Davis J, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gen Ther. 2012;23:1043-1053.
-
(2012)
Hum Gen Ther.
, vol.23
, pp. 1043-1053
-
-
Morgan, R.A.1
Johnson, L.A.2
Davis, J.3
-
84
-
-
84878931351
-
Targeting T cells to tumor cells using bispecific antibodies
-
Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17(3):385-392.
-
(2013)
Curr Opin Chem Biol.
, vol.17
, Issue.3
, pp. 385-392
-
-
Frankel, S.R.1
Baeuerle, P.A.2
-
85
-
-
79958041608
-
Bispecific antibodies engage Tcells for antitumor immunotherapy
-
Choi BD, Cai M, Bigner DD, et al. Bispecific antibodies engage Tcells for antitumor immunotherapy. Exp Opin Biol Ther. 2011;11(7):843-853.
-
(2011)
Exp Opin Biol Ther.
, vol.11
, Issue.7
, pp. 843-853
-
-
Choi, B.D.1
Cai, M.2
Bigner, D.D.3
-
86
-
-
79959312575
-
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
-
Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.18
, pp. 2493-2498
-
-
Topp, M.S.1
Kufer, P.2
Gokbuget, N.3
-
87
-
-
84871965330
-
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
-
Choi BD, Kuan CT, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA. 2013;110(1):270-275.
-
(2013)
Proc Natl Acad Sci USA.
, vol.110
, Issue.1
, pp. 270-275
-
-
Choi, B.D.1
Kuan, C.T.2
Cai, M.3
-
88
-
-
34548555781
-
Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: Implications for targeted therapies
-
Jarboe JS, Johnson KR, Choi Y, et al. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007;67(17):7983-7986.
-
(2007)
Cancer Res.
, vol.67
, Issue.17
, pp. 7983-7986
-
-
Jarboe, J.S.1
Johnson, K.R.2
Choi, Y.3
-
89
-
-
0025686126
-
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts
-
Bigner SH, Humphrey PA, Wong AJ, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 1990;50(24):8017-8022.
-
(1990)
Cancer Res.
, vol.50
, Issue.24
, pp. 8017-8022
-
-
Bigner, S.H.1
Humphrey, P.A.2
Wong, A.J.3
-
90
-
-
0021932240
-
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
-
Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313(5998):144-147.
-
(1985)
Nature
, vol.313
, Issue.5998
, pp. 144-147
-
-
Libermann, T.A.1
Nusbaum, H.R.2
Razon, N.3
-
91
-
-
0037463232
-
Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas
-
Tchirkov A, Rolhion C, Kemeny JL, et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Brit J Cancer. 2003;88(4):516-520.
-
(2003)
Brit J Cancer
, vol.88
, Issue.4
, pp. 516-520
-
-
Tchirkov, A.1
Rolhion, C.2
Kemeny, J.L.3
-
92
-
-
0032749913
-
Expression of the tumor-rejection antigen SART1 in brain tumors
-
Imaizumi T, Kuramoto T, Matsunaga K, et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer. 1999;83(6):760-764.
-
(1999)
Int J Cancer
, vol.83
, Issue.6
, pp. 760-764
-
-
Imaizumi, T.1
Kuramoto, T.2
Matsunaga, K.3
-
94
-
-
0033049977
-
Expression of MAGE and GAGE in high-grade brain tumors: A potential target for specific immunotherapy and diagnostic markers
-
Scarcella DL, Chow CW, Gonzales MF, et al. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res. 1999;5(2):335-341.
-
(1999)
Clin Cancer Res.
, vol.5
, Issue.2
, pp. 335-341
-
-
Scarcella, D.L.1
Chow, C.W.2
Gonzales, M.F.3
-
95
-
-
3142710121
-
HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells
-
Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004;64(14):4980-4986.
-
(2004)
Cancer Res.
, vol.64
, Issue.14
, pp. 4980-4986
-
-
Liu, G.1
Ying, H.2
Zeng, G.3
-
96
-
-
0036718859
-
∗0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
-
∗0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002;8(9):2851-2855.
-
(2002)
Clin Cancer Res.
, vol.8
, Issue.9
, pp. 2851-2855
-
-
Okano, F.1
Storkus, W.J.2
Chambers, W.H.3
-
97
-
-
0037083317
-
Quantitatively determined survivin expression levels are of prognostic value in human gliomas
-
Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20(4):1063-1068.
-
(2002)
J Clin Oncol.
, vol.20
, Issue.4
, pp. 1063-1068
-
-
Chakravarti, A.1
Noll, E.2
Black, P.M.3
-
98
-
-
3142692559
-
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
-
Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973-4979.
-
(2004)
Cancer Res.
, vol.64
, Issue.14
, pp. 4973-4979
-
-
Yu, J.S.1
Liu, G.2
Ying, H.3
-
99
-
-
0035107548
-
Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
-
Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61(3):842-847.
-
(2001)
Cancer Res.
, vol.61
, Issue.3
, pp. 842-847
-
-
Yu, J.S.1
Wheeler, C.J.2
Zeltzer, P.M.3
-
100
-
-
79951978155
-
Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma
-
Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330-336.
-
(2011)
J Clin Oncol.
, vol.29
, Issue.3
, pp. 330-336
-
-
Okada, H.1
Kalinski, P.2
Ueda, R.3
-
101
-
-
84872498982
-
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
-
Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62:125-135.
-
(2013)
Cancer Immunol Immunother.
, vol.62
, pp. 125-135
-
-
Phuphanich, S.1
Wheeler, C.J.2
Rudnick, J.D.3
-
102
-
-
0026548240
-
Structural alterations of the epidermal growth factor receptor gene in human gliomas
-
Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 1992;89(7):2965-2969.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, Issue.7
, pp. 2965-2969
-
-
Wong, A.J.1
Ruppert, J.M.2
Bigner, S.H.3
-
103
-
-
84863154888
-
Targeting EGF receptor variant III: Tumor-specific peptide vaccination for malignant gliomas
-
Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Exp Rev Vac. 2012;11(2):133-144.
-
(2012)
Exp Rev Vac.
, vol.11
, Issue.2
, pp. 133-144
-
-
Del Vecchio, C.A.1
Li, G.2
Wong, A.J.3
-
104
-
-
0141790037
-
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
-
Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247-4254.
-
(2003)
Clin Cancer Res.
, vol.9
, Issue.11
, pp. 4247-4254
-
-
Heimberger, A.B.1
Crotty, L.E.2
Archer, G.E.3
-
105
-
-
39149097490
-
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
-
Heimberger AB, Sun W, Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008;10(1):98-103.
-
(2008)
Neuro Oncol.
, vol.10
, Issue.1
, pp. 98-103
-
-
Heimberger, A.B.1
Sun, W.2
Hussain, S.F.3
-
106
-
-
79955784386
-
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
-
Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324-333.
-
(2011)
Neuro Oncol.
, vol.13
, Issue.3
, pp. 324-333
-
-
Sampson, J.H.1
Aldape, K.D.2
Archer, G.E.3
-
107
-
-
70350236627
-
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
-
Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773-2779.
-
(2009)
Mol Cancer Ther.
, vol.8
, Issue.10
, pp. 2773-2779
-
-
Sampson, J.H.1
Archer, G.E.2
Mitchell, D.A.3
-
108
-
-
78149254368
-
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
-
Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.31
, pp. 4722-4729
-
-
Sampson, J.H.1
Heimberger, A.B.2
Archer, G.E.3
-
109
-
-
53049089002
-
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines
-
Schmittling RJ, Archer GE, Mitchell DA, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Meth. 2008;339(1):74-81.
-
(2008)
J Immunol Meth.
, vol.339
, Issue.1
, pp. 74-81
-
-
Schmittling, R.J.1
Archer, G.E.2
Mitchell, D.A.3
-
110
-
-
84937534515
-
ReACT.: A Phase II Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma (GBM)
-
San Francisco, CA, Oxford Press
-
Reardon DA, Li G, Recht L, et al. ReACT.: A Phase II Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma (GBM). 4th Quadrennial Meeting of the World Federation of Neuro-Oncology/18th Annual Meeting of the Society for Neuro-Oncology. San Francisco, CA, Oxford Press, 2013.
-
(2013)
4th Quadrennial Meeting of the World Federation of Neuro-oncology/18th Annual Meeting of the Society for Neuro-oncology
-
-
Reardon, D.A.1
Li, G.2
Recht, L.3
-
111
-
-
0037096733
-
Human cytomegalovirus infection and expression in human malignant glioma
-
Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347-3350.
-
(2002)
Cancer Res.
, vol.62
, Issue.12
, pp. 3347-3350
-
-
Cobbs, C.S.1
Harkins, L.2
Samanta, M.3
-
112
-
-
39149136486
-
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
-
Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncol. 2008;10(1):10-18.
-
(2008)
Neuro-oncol.
, vol.10
, Issue.1
, pp. 10-18
-
-
Mitchell, D.A.1
Xie, W.2
Schmittling, R.3
-
113
-
-
48249102647
-
Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate
-
Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. New Engl J Med. 2008;359(5):539-541.
-
(2008)
New Engl J Med.
, vol.359
, Issue.5
, pp. 539-541
-
-
Prins, R.M.1
Cloughesy, T.F.2
Liau, L.M.3
-
114
-
-
79959834313
-
The detection of CMV pp65 and IE1 in glioblastoma multiforme
-
Lucas KG, Bao L, Bruggeman R, et al. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103(2):231-238.
-
(2011)
J Neurooncol.
, vol.103
, Issue.2
, pp. 231-238
-
-
Lucas, K.G.1
Bao, L.2
Bruggeman, R.3
-
115
-
-
79954502340
-
Detection of human cytomegalovirus in normal and neoplastic breast epithelium
-
Harkins LE, Matlaf LA, Soroceanu L, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae. 2010;1(1):8.
-
(2010)
Herpesviridae
, vol.1
, Issue.1
, pp. 8
-
-
Harkins, L.E.1
Matlaf, L.A.2
Soroceanu, L.3
-
116
-
-
82255169334
-
Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: Cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship
-
Melnick M, Sedghizadeh PP, Allen CM, et al. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp Mol Pathol. 2012;92(1):118-125.
-
(2012)
Exp Mol Pathol.
, vol.92
, Issue.1
, pp. 118-125
-
-
Melnick, M.1
Sedghizadeh, P.P.2
Allen, C.M.3
-
117
-
-
0042236661
-
High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma
-
Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170(3):998-1002.
-
(2003)
J Urol.
, vol.170
, Issue.3
, pp. 998-1002
-
-
Samanta, M.1
Harkins, L.2
Klemm, K.3
-
118
-
-
80053390591
-
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target
-
Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121(10):4043-4055.
-
(2011)
J Clin Invest.
, vol.121
, Issue.10
, pp. 4043-4055
-
-
Baryawno, N.1
Rahbar, A.2
Wolmer-Solberg, N.3
-
119
-
-
84883439743
-
Survival in patients with glioblastoma receiving valganciclovir
-
Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369(10):985-986.
-
(2013)
N Engl J Med.
, vol.369
, Issue.10
, pp. 985-986
-
-
Soderberg-Naucler, C.1
Rahbar, A.2
Stragliotto, G.3
-
120
-
-
84908233609
-
Cancer Immunology at the Crossroads: Functional Genomics Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
-
Hacohen N, Fritsch EF, Carter TA, et al. Cancer Immunology at the Crossroads: Functional Genomics Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer Immunol Res. 2013;1:11-15.
-
(2013)
Cancer Immunol Res.
, vol.1
, pp. 11-15
-
-
Hacohen, N.1
Fritsch, E.F.2
Carter, T.A.3
-
121
-
-
84862776855
-
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
-
Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400-404.
-
(2012)
Nature
, vol.482
, Issue.7385
, pp. 400-404
-
-
Matsushita, H.1
Vesely, M.D.2
Koboldt, D.C.3
-
122
-
-
27644534576
-
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
-
Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA. 2005;102(44):16013-16018.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, Issue.44
, pp. 16013-16018
-
-
Lennerz, V.1
Fatho, M.2
Gentilini, C.3
-
124
-
-
81255157774
-
Machine learning competition in immunology - Prediction of HLA class I binding peptides
-
Zhang GL, Ansari HR, Bradley P, et al. Machine learning competition in immunology - Prediction of HLA class I binding peptides. J Immunol Methods. 2011;374(1-2):1-4.
-
(2011)
J Immunol Methods
, vol.374
, Issue.1-2
, pp. 1-4
-
-
Zhang, G.L.1
Ansari, H.R.2
Bradley, P.3
-
125
-
-
84857725402
-
Exploiting the mutanome for tumor vaccination
-
Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081-1091.
-
(2012)
Cancer Res
, vol.72
, Issue.5
, pp. 1081-1091
-
-
Castle, J.C.1
Kreiter, S.2
Diekmann, J.3
-
126
-
-
0142089462
-
Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report
-
Liau LM, Black KL, Martin NA, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000;9(6):e8.
-
(2000)
Neurosurg Focus
, vol.9
, Issue.6
, pp. e8
-
-
Liau, L.M.1
Black, K.L.2
Martin, N.A.3
-
127
-
-
23044479028
-
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
-
Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.
-
(2005)
Clin Cancer Res.
, vol.11
, Issue.15
, pp. 5515-5525
-
-
Liau, L.M.1
Prins, R.M.2
Kiertscher, S.M.3
-
128
-
-
49649113879
-
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
-
De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10):3098-3104.
-
(2008)
Clin Cancer Res.
, vol.14
, Issue.10
, pp. 3098-3104
-
-
De Vleeschouwer, S.1
Fieuws, S.2
Rutkowski, S.3
-
129
-
-
11144356171
-
Transient local response and persistent tumor control in a child with recurrent malignant glioma: Treatment with combination therapy including dendritic cell therapy. Case report
-
De Vleeschouwer S, Van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg. 2004;100(5 Suppl Pediatrics):492-497.
-
(2004)
J Neurosurg
, vol.100
, Issue.5
, pp. 492-497
-
-
De Vleeschouwer, S.1
Van Calenbergh, F.2
Demaerel, P.3
-
130
-
-
9144247794
-
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
-
Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91(9):1656-1662.
-
(2004)
Br J Cancer
, vol.91
, Issue.9
, pp. 1656-1662
-
-
Rutkowski, S.1
De Vleeschouwer, S.2
Kaempgen, E.3
-
131
-
-
20344372430
-
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
-
Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160-4167.
-
(2005)
Clin Cancer Res.
, vol.11
, pp. 4160-4167
-
-
Yamanaka, R.1
Homma, J.2
Yajima, N.3
-
132
-
-
79955591522
-
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
-
Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011;34(4):382-389.
-
(2011)
J Immunother
, vol.34
, Issue.4
, pp. 382-389
-
-
Fadul, C.E.1
Fisher, J.L.2
Hampton, T.H.3
-
133
-
-
79952711945
-
Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
-
Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615.
-
(2011)
Clin Cancer Res.
, vol.17
, Issue.6
, pp. 1603-1615
-
-
Prins, R.M.1
Soto, H.2
Konkankit, V.3
-
134
-
-
48649096955
-
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
-
Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68(14):5955-5964.
-
(2008)
Cancer Res.
, vol.68
, Issue.14
, pp. 5955-5964
-
-
Wheeler, C.J.1
Black, K.L.2
Liu, G.3
-
135
-
-
77956061272
-
Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study
-
Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 2010;99(2):261-272.
-
(2010)
J Neurooncol.
, vol.99
, Issue.2
, pp. 261-272
-
-
Ardon, H.1
Van Gool, S.2
Lopes, I.S.3
-
136
-
-
84870985481
-
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial
-
Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012;61:2033-2044.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 2033-2044
-
-
Ardon, H.1
Van Gool, S.W.2
Verschuere, T.3
-
137
-
-
0033957941
-
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
-
Heimberger AB, Crotty LE, Archer GE, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol. 2000;103(1):16-25.
-
(2000)
J Neuroimmunol.
, vol.103
, Issue.1
, pp. 16-25
-
-
Heimberger, A.B.1
Crotty, L.E.2
Archer, G.E.3
-
138
-
-
0033007570
-
Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
-
Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90(6):1115-1124.
-
(1999)
J Neurosurg
, vol.90
, Issue.6
, pp. 1115-1124
-
-
Liau, L.M.1
Black, K.L.2
Prins, R.M.3
-
139
-
-
78449298442
-
Cancer stem cells in the central nervous system - A critical review
-
Prestegarden L, Enger PO. Cancer stem cells in the central nervous system - a critical review. Cancer Res. 2010;70(21):8255-8258.
-
(2010)
Cancer Res.
, vol.70
, Issue.21
, pp. 8255-8258
-
-
Prestegarden, L.1
Enger, P.O.2
-
140
-
-
46449115281
-
Stemcell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
-
Murat A, Migliavacca E, Gorlia T, et al. Stemcell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015-3024.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.18
, pp. 3015-3024
-
-
Murat, A.1
Migliavacca, E.2
Gorlia, T.3
-
141
-
-
33845317573
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
-
Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
-
(2006)
Nature
, vol.444
, Issue.7120
, pp. 756-760
-
-
Bao, S.1
Wu, Q.2
McLendon, R.E.3
-
142
-
-
78049270536
-
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
-
Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncol. 2010;12(11):1113-1125.
-
(2010)
Neuro-oncol.
, vol.12
, Issue.11
, pp. 1113-1125
-
-
Wu, A.1
Wei, J.2
Kong, L.Y.3
-
143
-
-
76049114698
-
Immunobiological characterization of cancer stem cells isolated from glioblastoma patients
-
Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16(3):800-813.
-
(2010)
Clin Cancer Res.
, vol.16
, Issue.3
, pp. 800-813
-
-
Di Tomaso, T.1
Mazzoleni, S.2
Wang, E.3
-
144
-
-
69249149701
-
Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
-
Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem cells. 2009;27(8):1734-1740.
-
(2009)
Stem Cells
, vol.27
, Issue.8
, pp. 1734-1740
-
-
Xu, Q.1
Liu, G.2
Yuan, X.3
-
145
-
-
33751297619
-
Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas
-
Pellegatta S, Poliani PL, Corno D, et al. Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas. Cancer Res. 2006;66(21):10247-10252.
-
(2006)
Cancer Res.
, vol.66
, Issue.21
, pp. 10247-10252
-
-
Pellegatta, S.1
Poliani, P.L.2
Corno, D.3
-
146
-
-
0032695108
-
Natural adjuvants: Endogenous activators of dendritic cells
-
Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5(11):1249-1255.
-
(1999)
Nat Med.
, vol.5
, Issue.11
, pp. 1249-1255
-
-
Gallucci, S.1
Lolkema, M.2
Matzinger, P.3
-
147
-
-
84893073441
-
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial
-
Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014;16(2):274-279.
-
(2014)
Neuro Oncol.
, vol.16
, Issue.2
, pp. 274-279
-
-
Bloch, O.1
Crane, C.A.2
Fuks, Y.3
-
148
-
-
84871951211
-
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein
-
Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19(1):205-214.
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.1
, pp. 205-214
-
-
Crane, C.A.1
Han, S.J.2
Ahn, B.3
-
150
-
-
34248204110
-
DC-based cancer vaccines
-
Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195-1203.
-
(2007)
J Clin Invest.
, vol.117
, Issue.5
, pp. 1195-1203
-
-
Gilboa, E.1
-
151
-
-
84859709790
-
New developments in vaccine research-unveiling the secret of vaccine adjuvants
-
de Veer M, Meeusen E. New developments in vaccine research-unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195-204.
-
(2011)
Discov Med.
, vol.12
, Issue.64
, pp. 195-204
-
-
De Veer, M.1
Meeusen, E.2
-
152
-
-
79955859969
-
Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines
-
Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol. 2011;30(2-3):150-182.
-
(2011)
Int Rev Immunol.
, vol.30
, Issue.2-3
, pp. 150-182
-
-
Chiang, C.L.1
Kandalaft, L.E.2
Coukos, G.3
-
154
-
-
84858780815
-
Cancer immunotherapy via dendritic cells
-
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-277.
-
(2012)
Nat Rev Cancer
, vol.12
, Issue.4
, pp. 265-277
-
-
Palucka, K.1
Banchereau, J.2
-
155
-
-
17644370329
-
Cell biology of antigen processing in vitro and in vivo
-
Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Ann Rev Immunol. 2005;23:975-1028.
-
(2005)
Ann Rev Immunol.
, vol.23
, pp. 975-1028
-
-
Trombetta, E.S.1
Mellman, I.2
-
156
-
-
69549103141
-
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo
-
Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009;206(9):1853-1862.
-
(2009)
J Exp Med.
, vol.206
, Issue.9
, pp. 1853-1862
-
-
Darrasse-Jeze, G.1
Deroubaix, S.2
Mouquet, H.3
-
157
-
-
77957982756
-
Toll-like receptor agonists: Are they good adjuvants?
-
Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants?. Cancer J. 2010;16(4):382-391.
-
(2010)
Cancer J.
, vol.16
, Issue.4
, pp. 382-391
-
-
Gnjatic, S.1
Sawhney, N.B.2
Bhardwaj, N.3
-
158
-
-
84863000097
-
Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma
-
Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol. 2012;746:95-108.
-
(2012)
Adv Exp Med Biol.
, vol.746
, pp. 95-108
-
-
Ursu, R.1
Carpentier, A.F.2
-
159
-
-
29644446061
-
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity
-
Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157-164.
-
(2006)
J Immunol.
, vol.176
, Issue.1
, pp. 157-164
-
-
Prins, R.M.1
Craft, N.2
Bruhn, K.W.3
-
161
-
-
0034060821
-
Keyhole limpet haemocyanin in experimental bladder cancer: Literature review and own results
-
Linn JF, Black P, Derksen K, et al. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results. Eur Urol. 2000;37(Suppl 3):34-40.
-
(2000)
Eur Urol.
, vol.37
, pp. 34-40
-
-
Linn, J.F.1
Black, P.2
Derksen, K.3
-
162
-
-
84860798836
-
The regulation of the development and function of dendritic cell subsets by GM-CSF: More than a hematopoietic growth factor
-
Zhan Y, Xu Y, Lew AM. The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Mol Immunol. 2012;52(1):30-37.
-
(2012)
Mol Immunol.
, vol.52
, Issue.1
, pp. 30-37
-
-
Zhan, Y.1
Xu, Y.2
Lew, A.M.3
-
163
-
-
0037441842
-
Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
-
Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21(4):624-630.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.4
, pp. 624-630
-
-
Salgia, R.1
Lynch, T.2
Skarin, A.3
-
164
-
-
0141576738
-
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
-
Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21(17):3343-3350.
-
(2003)
J Clin Oncol.
, vol.21
, Issue.17
, pp. 3343-3350
-
-
Soiffer, R.1
Hodi, F.S.2
Haluska, F.3
-
165
-
-
22144497779
-
Vaccines in cancer: GVAX, a GM-CSF gene vaccine
-
Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Exp Rev Vaccines. 2005;4(3):259-274.
-
(2005)
Exp Rev Vaccines
, vol.4
, Issue.3
, pp. 259-274
-
-
Nemunaitis, J.1
-
166
-
-
33847258205
-
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
-
Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18(2):226-232.
-
(2007)
Ann Oncol.
, vol.18
, Issue.2
, pp. 226-232
-
-
Parmiani, G.1
Castelli, C.2
Pilla, L.3
-
167
-
-
77952125524
-
Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental?
-
Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?. Exp Rev Vaccines. 2010;9(5):519-525.
-
(2010)
Exp Rev Vaccines
, vol.9
, Issue.5
, pp. 519-525
-
-
Clive, K.S.1
Tyler, J.A.2
Clifton, G.T.3
-
168
-
-
34447121852
-
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF
-
Jinushi M, Nakazaki Y, Dougan M, et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 2007;117(7):1902-1913.
-
(2007)
J Clin Invest.
, vol.117
, Issue.7
, pp. 1902-1913
-
-
Jinushi, M.1
Nakazaki, Y.2
Dougan, M.3
-
169
-
-
84872184215
-
Vaccine injection site matters: Qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model
-
Ohlfest JR, Andersen BM, Litterman AJ, et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol. 2013;190(2):613-620.
-
(2013)
J Immunol.
, vol.190
, Issue.2
, pp. 613-620
-
-
Ohlfest, J.R.1
Andersen, B.M.2
Litterman, A.J.3
-
170
-
-
0142179258
-
Thymic CD8+ T-cell production strongly influences tumor antigen recognition and agedependent glioma mortality
-
Wheeler CJ, Black KL, Liu G, et al. Thymic CD8+ T-cell production strongly influences tumor antigen recognition and agedependent glioma mortality. J Immunol. 2003;171:4927-4933.
-
(2003)
J Immunol.
, vol.171
, pp. 4927-4933
-
-
Wheeler, C.J.1
Black, K.L.2
Liu, G.3
-
171
-
-
84870982871
-
Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination
-
De Vleeschouwer S, Ardon H, Van Calenbergh F, et al. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother. 2012;61:2105-2112.
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 2105-2112
-
-
De Vleeschouwer, S.1
Ardon, H.2
Van Calenbergh, F.3
-
172
-
-
84886943535
-
The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
-
Pellegatta S, Eoli M, Frigerio S, et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology. 2013;2(3):e23401.
-
(2013)
Oncoimmunology
, vol.2
, Issue.3
, pp. e23401
-
-
Pellegatta, S.1
Eoli, M.2
Frigerio, S.3
-
173
-
-
84857547272
-
A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
-
Sampson JH, Schmittling RJ, Archer GE, et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PloS One. 2012;7(2):e31046.
-
(2012)
PloS One
, vol.7
, Issue.2
, pp. e31046
-
-
Sampson, J.H.1
Schmittling, R.J.2
Archer, G.E.3
-
174
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med. 2011;364(26):2517-2526.
-
(2011)
New Engl J Med.
, vol.364
, Issue.26
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
175
-
-
65349119978
-
CD28 and CTLA-4 coreceptor expression and signal transduction
-
Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12-26.
-
(2009)
Immunol Rev.
, vol.229
, Issue.1
, pp. 12-26
-
-
Rudd, C.E.1
Taylor, A.2
Schneider, H.3
-
176
-
-
0028675006
-
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.[erratum appears in Immunity 1995 Feb;2 (2): Following 203]
-
Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.[erratum appears in Immunity 1995 Feb;2 (2) :following 203]. Immunity. 1994;1(9):793-801.
-
(1994)
Immunity
, vol.1
, Issue.9
, pp. 793-801
-
-
Linsley, P.S.1
Greene, J.L.2
Brady, W.3
-
177
-
-
53749094183
-
CTLA-4 control over Foxp3+ regulatory T cell function
-
Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271-275.
-
(2008)
Science
, vol.322
, Issue.5899
, pp. 271-275
-
-
Wing, K.1
Onishi, Y.2
Prieto-Martin, P.3
-
178
-
-
68149155982
-
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
-
Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-1725.
-
(2009)
J Exp Med.
, vol.206
, Issue.8
, pp. 1717-1725
-
-
Peggs, K.S.1
Quezada, S.A.2
Chambers, C.A.3
-
179
-
-
61349139964
-
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
-
Liu Y, Yu Y, Yang S, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother. 2009;58(5):687-697.
-
(2009)
Cancer Immunol Immunother
, vol.58
, Issue.5
, pp. 687-697
-
-
Liu, Y.1
Yu, Y.2
Yang, S.3
-
180
-
-
0028791059
-
Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
-
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270(5238):985-988.
-
(1995)
Science
, vol.270
, Issue.5238
, pp. 985-988
-
-
Waterhouse, P.1
Penninger, J.M.2
Timms, E.3
-
181
-
-
38449115210
-
PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues
-
Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007;179(8):5064-5070.
-
(2007)
J Immunol.
, vol.179
, Issue.8
, pp. 5064-5070
-
-
Keir, M.E.1
Freeman, G.J.2
Sharpe, A.H.3
-
182
-
-
0026700235
-
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
-
Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-3895.
-
(1992)
EMBO J.
, vol.11
, Issue.11
, pp. 3887-3895
-
-
Ishida, Y.1
Agata, Y.2
Shibahara, K.3
-
183
-
-
32544459770
-
Restoring function in exhausted CD8T cells during chronic viral infection
-
Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8T cells during chronic viral infection. Nature. 2006;439(7077):682-687.
-
(2006)
Nature
, vol.439
, Issue.7077
, pp. 682-687
-
-
Barber, D.L.1
Wherry, E.J.2
Masopust, D.3
-
184
-
-
0034596948
-
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
-
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.
-
(2000)
J Exp Med.
, vol.192
, Issue.7
, pp. 1027-1034
-
-
Freeman, G.J.1
Long, A.J.2
Iwai, Y.3
-
185
-
-
62249172189
-
Enhancing SIV-specific immunity in vivo by PD-1 blockade
-
Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206-210.
-
(2009)
Nature
, vol.458
, Issue.7235
, pp. 206-210
-
-
Velu, V.1
Titanji, K.2
Zhu, B.3
-
186
-
-
80051698136
-
IL-18 induces PD-1-dependent immunosuppression in cancer
-
Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16):5393-5399.
-
(2011)
Cancer Res.
, vol.71
, Issue.16
, pp. 5393-5399
-
-
Terme, M.1
Ullrich, E.2
Aymeric, L.3
-
187
-
-
44349150012
-
Inhibitory B7-family molecules in the tumour microenvironment
-
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
-
(2008)
Nat Rev Immunol.
, vol.8
, Issue.6
, pp. 467-477
-
-
Zou, W.1
Chen, L.2
-
188
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
-
(2012)
Sci Transl Med.
, vol.4
, Issue.127
, pp. 127ra37
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
-
189
-
-
33846118474
-
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
-
Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-88.
-
(2007)
Nat Med.
, vol.13
, Issue.1
, pp. 84-88
-
-
Parsa, A.T.1
Waldron, J.S.2
Panner, A.3
-
190
-
-
73249125835
-
B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells
-
Yao Y, Tao R, Wang X, et al. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009;11(6):757-766.
-
(2009)
Neuro Oncol.
, vol.11
, Issue.6
, pp. 757-766
-
-
Yao, Y.1
Tao, R.2
Wang, X.3
-
191
-
-
0242442492
-
Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis
-
Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63(21):7462-7467.
-
(2003)
Cancer Res.
, vol.63
, Issue.21
, pp. 7462-7467
-
-
Wintterle, S.1
Schreiner, B.2
Mitsdoerffer, M.3
-
192
-
-
77955665451
-
Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions
-
Avril T, Saikali S, Vauleon E, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol. 2010;225(1-2):22-33.
-
(2010)
J Neuroimmunol.
, vol.225
, Issue.1-2
, pp. 22-33
-
-
Avril, T.1
Saikali, S.2
Vauleon, E.3
-
193
-
-
22544486023
-
B7-homolog 1 expression by human glioma: A new mechanism of immune evasion
-
Wilmotte R, Burkhardt K, Kindler V, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 2005;16(10):1081-1085.
-
(2005)
Neuroreport
, vol.16
, Issue.10
, pp. 1081-1085
-
-
Wilmotte, R.1
Burkhardt, K.2
Kindler, V.3
-
194
-
-
68949085209
-
Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
-
Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11(4):394-402.
-
(2009)
Neuro Oncol.
, vol.11
, Issue.4
, pp. 394-402
-
-
Jacobs, J.F.1
Idema, A.J.2
Bol, K.F.3
-
195
-
-
34247502076
-
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function
-
Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13(7):2158-2167.
-
(2007)
Clin Cancer Res.
, vol.13
, Issue.7
, pp. 2158-2167
-
-
Fecci, P.E.1
Ochiai, H.2
Mitchell, D.A.3
-
196
-
-
84890846323
-
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection
-
Vom Berg J, Vrohlings M, Haller S, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210(13):2803-2811.
-
(2013)
J Exp Med.
, vol.210
, Issue.13
, pp. 2803-2811
-
-
Vom Berg, J.1
Vrohlings, M.2
Haller, S.3
-
197
-
-
84877581852
-
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
-
Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-349.
-
(2013)
Int J Radiat Oncol Biol Phys.
, vol.86
, Issue.2
, pp. 343-349
-
-
Zeng, J.1
See, A.P.2
Phallen, J.3
-
198
-
-
84865553349
-
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
-
Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. 2012;23(Suppl 8):viii15-21.
-
(2012)
Ann Oncol.
, vol.23
, pp. viii15-viii21
-
-
Wolchok, J.1
-
199
-
-
84859393995
-
CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma
-
Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.
-
(2012)
Clin Cancer Res.
, vol.18
, Issue.7
, pp. 2039-2047
-
-
Prieto, P.A.1
Yang, J.C.2
Sherry, R.M.3
-
200
-
-
84874605864
-
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
-
Ribas A, Kefford R, Marshall MA, et al. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. J Clin Oncol. 2013;31:616-622.
-
(2013)
J Clin Oncol.
, vol.31
, pp. 616-622
-
-
Ribas, A.1
Kefford, R.2
Marshall, M.A.3
-
201
-
-
84863911486
-
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
-
Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.17
, pp. 2046-2054
-
-
Lynch, T.J.1
Bondarenko, I.2
Luft, A.3
-
202
-
-
84860455345
-
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial
-
Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-508.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.5
, pp. 501-508
-
-
Madan, R.A.1
Mohebtash, M.2
Arlen, P.M.3
-
203
-
-
84862754605
-
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
-
McNeel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012;61(7):1137-1147.
-
(2012)
Cancer Immunol Immunother.
, vol.61
, Issue.7
, pp. 1137-1147
-
-
McNeel, D.G.1
Smith, H.A.2
Eickhoff, J.C.3
-
204
-
-
77954230122
-
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells
-
Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2012;16(13):3485-3494.
-
(2012)
Clin Cancer Res.
, vol.16
, Issue.13
, pp. 3485-3494
-
-
Vonderheide, R.H.1
LoRusso, P.M.2
Khalil, M.3
-
205
-
-
77955292303
-
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
-
Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(21):3485-3490.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.21
, pp. 3485-3490
-
-
Chung, K.Y.1
Gore, I.2
Fong, L.3
-
206
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
-
(2007)
J Immunother.
, vol.30
, Issue.8
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
-
207
-
-
77958050577
-
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
-
Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828-833.
-
(2010)
J Immunother.
, vol.33
, Issue.8
, pp. 828-833
-
-
Royal, R.E.1
Levy, C.2
Turner, K.3
-
208
-
-
84884703526
-
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial
-
Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104-1111.
-
(2013)
Lancet Oncol.
, vol.14
, Issue.11
, pp. 1104-1111
-
-
Calabro, L.1
Morra, A.2
Fonsatti, E.3
-
209
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
-
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
-
(2013)
N Engl J Med.
, vol.369
, Issue.2
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
-
210
-
-
84864052441
-
Management of immune-related adverse events and kinetics of response with ipilimumab
-
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.21
, pp. 2691-2697
-
-
Weber, J.S.1
Kahler, K.C.2
Hauschild, A.3
-
211
-
-
84886443514
-
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
-
Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clin Cancer Res. 2013;19(19):5300-5309.
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.19
, pp. 5300-5309
-
-
Ott, P.A.1
Hodi, F.S.2
Robert, C.3
-
212
-
-
84876678621
-
Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma
-
Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675-1682.
-
(2013)
Cancer.
, vol.119
, Issue.9
, pp. 1675-1682
-
-
Weber, J.S.1
Dummer, R.2
De Pril, V.3
-
213
-
-
84881186333
-
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
-
Feng Y, Roy A, Masson E, et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977-3986.
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.14
, pp. 3977-3986
-
-
Feng, Y.1
Roy, A.2
Masson, E.3
-
214
-
-
84860446616
-
Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
-
Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.5
, pp. 459-465
-
-
Margolin, K.1
Ernstoff, M.S.2
Hamid, O.3
-
215
-
-
84877043331
-
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
-
Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23(3):191-195.
-
(2013)
Melanoma Res.
, vol.23
, Issue.3
, pp. 191-195
-
-
Mathew, M.1
Tam, M.2
Ott, P.A.3
-
216
-
-
84904216679
-
Ipilimumab and radiation therapy for melanoma brain metastases
-
Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899-906.
-
(2013)
Cancer Med.
, vol.2
, Issue.6
, pp. 899-906
-
-
Silk, A.W.1
Bassetti, M.F.2
West, B.T.3
-
217
-
-
51149116051
-
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature clinical practice
-
Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature clinical practice. Oncology. 2008;5(9):557-561.
-
(2008)
Oncology
, vol.5
, Issue.9
, pp. 557-561
-
-
Hodi, F.S.1
Oble, D.A.2
Drappatz, J.3
-
218
-
-
84879112954
-
Profound impairment of adaptive immune responses by alkylating chemotherapy
-
Litterman AJ, Zellmer DM, Grinnen KL, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013;190(12):6259-6268.
-
(2013)
J Immunol.
, vol.190
, Issue.12
, pp. 6259-6268
-
-
Litterman, A.J.1
Zellmer, D.M.2
Grinnen, K.L.3
-
219
-
-
84912052604
-
The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer
-
Epub ahead of print
-
Campian J, Sarai G, Ye X, et al. The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2013. doi: 10.1002/hed.23535. [Epub ahead of print].
-
(2013)
Head Neck.
-
-
Campian, J.1
Sarai, G.2
Ye, X.3
-
220
-
-
84875048243
-
Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer
-
Campian JL, Ye X, Brock M, et al. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest. 2013;31(3):183-188.
-
(2013)
Cancer Invest.
, vol.31
, Issue.3
, pp. 183-188
-
-
Campian, J.L.1
Ye, X.2
Brock, M.3
-
221
-
-
84970918518
-
The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma
-
epub
-
Wild AT, Ye X, Ellsworth SG, et al. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol. 2013. epub.
-
(2013)
Am J Clin Oncol.
-
-
Wild, A.T.1
Ye, X.2
Ellsworth, S.G.3
-
222
-
-
79952390627
-
Immune parameters affecting the efficacy of chemotherapeutic regimens
-
Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-160.
-
(2011)
Nat Rev Clin Oncol.
, vol.8
, Issue.3
, pp. 151-160
-
-
Zitvogel, L.1
Kepp, O.2
Kroemer, G.3
-
223
-
-
49249127841
-
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies
-
Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68(11):4026-4030.
-
(2008)
Cancer Res.
, vol.68
, Issue.11
, pp. 4026-4030
-
-
Apetoh, L.1
Tesniere, A.2
Ghiringhelli, F.3
-
224
-
-
84875068031
-
Myeloablative temozolomide enhances CD8 (+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice
-
Sanchez-Perez LA, Choi BD, Archer GE, et al. Myeloablative temozolomide enhances CD8 (+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082.
-
(2013)
PLoS One
, vol.8
, Issue.3
, pp. e59082
-
-
Sanchez-Perez, L.A.1
Choi, B.D.2
Archer, G.E.3
-
225
-
-
84866920006
-
Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
-
McCoy MJ, Lake RA, van der Most RG, et al. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer. 2012;107(7):1107-1115.
-
(2012)
Br J Cancer
, vol.107
, Issue.7
, pp. 1107-1115
-
-
McCoy, M.J.1
Lake, R.A.2
Van Der Most, R.G.3
-
226
-
-
33847368549
-
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
-
Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-648.
-
(2007)
Cancer Immunol Immunother
, vol.56
, Issue.5
, pp. 641-648
-
-
Ghiringhelli, F.1
Menard, C.2
Puig, P.E.3
-
227
-
-
25144466458
-
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
-
Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713-6721.
-
(2005)
Clin Cancer Res.
, vol.11
, Issue.18
, pp. 6713-6721
-
-
Suzuki, E.1
Kapoor, V.2
Jassar, A.S.3
-
228
-
-
84872086179
-
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
-
Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19(1):57-64.
-
(2013)
Nat Med.
, vol.19
, Issue.1
, pp. 57-64
-
-
Bruchard, M.1
Mignot, G.2
Derangere, V.3
-
229
-
-
77956911325
-
Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition
-
Fine JH, Chen P, Mesci A, et al. Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res. 2010;70(18):7102-7113.
-
(2010)
Cancer Res.
, vol.70
, Issue.18
, pp. 7102-7113
-
-
Fine, J.H.1
Chen, P.2
Mesci, A.3
-
230
-
-
81155154274
-
Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control
-
Hong M, Puaux AL, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71(22):6997-7009.
-
(2011)
Cancer Res.
, vol.71
, Issue.22
, pp. 6997-7009
-
-
Hong, M.1
Puaux, A.L.2
Huang, C.3
-
231
-
-
84886944998
-
Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
-
Demaria S, Pilones KA, Formenti SC, et al. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology. 2013;2(3):e23127.
-
(2013)
Oncoimmunology
, vol.2
, Issue.3
, pp. e23127
-
-
Demaria, S.1
Pilones, K.A.2
Formenti, S.C.3
-
232
-
-
84857815877
-
Immunologic correlates of the abscopal effect in a patient with melanoma
-
Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. New Engl J Med. 2012;366(10):925-931.
-
(2012)
New Engl J Med.
, vol.366
, Issue.10
, pp. 925-931
-
-
Postow, M.A.1
Callahan, M.K.2
Barker, C.A.3
-
233
-
-
84876522514
-
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
-
Lesterhuis WJ, Salmons J, Nowak AK, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013;8(4):e61895.
-
(2013)
PLoS One
, vol.8
, Issue.4
, pp. e61895
-
-
Lesterhuis, W.J.1
Salmons, J.2
Nowak, A.K.3
-
234
-
-
0032400862
-
Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
-
Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150-4166.
-
(1998)
Blood.
, vol.92
, Issue.11
, pp. 4150-4166
-
-
Gabrilovich, D.1
Ishida, T.2
Oyama, T.3
-
235
-
-
0029842830
-
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
-
Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103.
-
(1996)
Nat Med.
, vol.2
, Issue.10
, pp. 1096-1103
-
-
Gabrilovich, D.I.1
Chen, H.L.2
Girgis, K.R.3
-
236
-
-
34047131797
-
Vascular endothelial growth factor and immunosuppression in cancer: Current knowledge and potential for new therapy
-
Johnson BF, Clay TM, Hobeika AC, et al. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Exp Opin Biol Ther. 2007;7(4):449-460.
-
(2007)
Exp Opin Biol Ther.
, vol.7
, Issue.4
, pp. 449-460
-
-
Johnson, B.F.1
Clay, T.M.2
Hobeika, A.C.3
-
237
-
-
79952281184
-
Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
-
Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30(1):83-95.
-
(2011)
Cancer Metastasis Rev.
, vol.30
, Issue.1
, pp. 83-95
-
-
Tartour, E.1
Pere, H.2
Maillere, B.3
-
238
-
-
77955406159
-
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
-
Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171-6180.
-
(2010)
Cancer Res.
, vol.70
, Issue.15
, pp. 6171-6180
-
-
Shrimali, R.K.1
Yu, Z.2
Theoret, M.R.3
-
239
-
-
34447117552
-
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
-
Manning EA, Ullman JG, Leatherman JM, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007;13(13):3951-3959.
-
(2007)
Clin Cancer Res.
, vol.13
, Issue.13
, pp. 3951-3959
-
-
Manning, E.A.1
Ullman, J.G.2
Leatherman, J.M.3
-
240
-
-
84877870613
-
Vascular normalization as an emerging strategy to enhance cancer immunotherapy
-
Huang Y, Goel S, Duda DG, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943-2948.
-
(2013)
Cancer Res.
, vol.73
, Issue.10
, pp. 2943-2948
-
-
Huang, Y.1
Goel, S.2
Duda, D.G.3
-
241
-
-
80052919974
-
Monoclonal antibody blockade of IL-2 receptor {alpha} during lymphopenia selectively depletes regulatory T cells in mice and humans
-
Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor {alpha} during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011;118(11):3003-3012.
-
(2011)
Blood
, vol.118
, Issue.11
, pp. 3003-3012
-
-
Mitchell, D.A.1
Cui, X.2
Schmittling, R.J.3
-
242
-
-
33845885624
-
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
-
Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006;12(14 Pt 1):4294-4305.
-
(2006)
Clin Cancer Res.
, vol.12
, Issue.14
, pp. 4294-4305
-
-
Fecci, P.E.1
Sweeney, A.E.2
Grossi, P.M.3
-
243
-
-
79954559096
-
T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells
-
Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev. 2011;241(1):63-76.
-
(2011)
Immunol Rev.
, vol.241
, Issue.1
, pp. 63-76
-
-
Cheng, G.1
Yu, A.2
Malek, T.R.3
-
244
-
-
84879104519
-
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
-
Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591-3603.
-
(2013)
Cancer Res.
, vol.73
, Issue.12
, pp. 3591-3603
-
-
Duraiswamy, J.1
Kaluza, K.M.2
Freeman, G.J.3
-
245
-
-
84861233216
-
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors
-
Agarwalla P, Barnard Z, Fecci P, et al. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012;35(5):385-389.
-
(2012)
J Immunother
, vol.35
, Issue.5
, pp. 385-389
-
-
Agarwalla, P.1
Barnard, Z.2
Fecci, P.3
-
246
-
-
84879874041
-
Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model
-
Williams EL, Dunn SN, James S, et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res. 2013;19(13):3545-3555.
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.13
, pp. 3545-3555
-
-
Williams, E.L.1
Dunn, S.N.2
James, S.3
-
247
-
-
84875689651
-
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
-
Wada S, Jackson CM, Yoshimura K, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.
-
(2013)
J Transl Med.
, vol.11
, pp. 89
-
-
Wada, S.1
Jackson, C.M.2
Yoshimura, K.3
-
248
-
-
84860436621
-
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: A phase 1 dose-escalation trial
-
van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509-517.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.5
, pp. 509-517
-
-
Van Den Eertwegh, A.J.1
Versluis, J.2
Van Den Berg, H.P.3
-
249
-
-
84892866206
-
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
-
Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311-4318.
-
(2013)
J Clin Oncol.
, vol.31
, Issue.34
, pp. 4311-4318
-
-
Weber, J.S.1
Kudchadkar, R.R.2
Yu, B.3
-
250
-
-
77749279776
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
-
Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107(9):4275-4280.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.9
, pp. 4275-4280
-
-
Curran, M.A.1
Montalvo, W.2
Yagita, H.3
-
251
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
-
(2013)
N Engl J Med.
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
-
252
-
-
77951625266
-
Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group
-
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.11
, pp. 1963-1972
-
-
Wen, P.Y.1
Macdonald, D.R.2
Reardon, D.A.3
-
253
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
-
(2009)
Clin Cancer Res.
, vol.15
, Issue.23
, pp. 7412-7420
-
-
Wolchok, J.D.1
Hoos, A.2
O'Day, S.3
-
254
-
-
0037099539
-
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
-
author reply 3176-3177
-
Wolchok JD, Chapman PB. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002;20(14):3176. author reply 3176-3177.
-
(2002)
J Clin Oncol.
, vol.20
, Issue.14
, pp. 3176
-
-
Wolchok, J.D.1
Chapman, P.B.2
-
255
-
-
79955667525
-
Do we need novel radiologic response criteria for brain tumor immunotherapy?
-
Okada H, Pollack IF. Do we need novel radiologic response criteria for brain tumor immunotherapy?. Exp Rev Neurotherap. 2011;11(5):619-622.
-
(2011)
Exp Rev Neurotherap.
, vol.11
, Issue.5
, pp. 619-622
-
-
Okada, H.1
Pollack, I.F.2
-
256
-
-
79953816808
-
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
-
Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011;60(3):433-442.
-
(2011)
Cancer Immunol Immunother.
, vol.60
, Issue.3
, pp. 433-442
-
-
Disis, M.L.1
-
257
-
-
0242329784
-
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial
-
Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89(7):1172-1179.
-
(2003)
Br J Cancer.
, vol.89
, Issue.7
, pp. 1172-1179
-
-
Yamanaka, R.1
Abe, T.2
Yajima, N.3
-
258
-
-
84881024704
-
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)
-
McNeil LK, Price L, Britten CM, et al. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2013;83(8):728-738.
-
(2013)
Cytometry A.
, vol.83
, Issue.8
, pp. 728-738
-
-
McNeil, L.K.1
Price, L.2
Britten, C.M.3
-
259
-
-
74349117866
-
Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: A paradoxical mechanism of immune evasion
-
Han SJ, Ahn BJ, Waldron JS, et al. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport. 2009;20(18):1597-1602.
-
(2009)
Neuroreport
, vol.20
, Issue.18
, pp. 1597-1602
-
-
Han, S.J.1
Ahn, B.J.2
Waldron, J.S.3
|